올리고뉴클레오티드 시장

The global market for oligonucleotides was valued at $9.1 billion in 2025 and is estimated to reach $15.7 billion by 2030, at a compound annual growth rate (CAGR) of 11.5% from 2025 through 2030.

The North American market for oligonucleotides was valued at $3.7 billion in 2025 and is estimated to reach $6.3 billion by 2030, at a CAGR of 11.3% from 2025 through 2030.

The Asia-Pacific market for oligonucleotides was valued at $2.2 billion in 2025 and is estimated to reach $4 billion by 2030, at a CAGR of 13.3% from 2025 through 2030.

Report Scope

The report provides an overview of the oligonucleotides market and analyzes market trends. It includes global revenue ($ Million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented by product type, application and region.

By product type, the market is segmented into oligonucleotide drugs, synthesized oligos, equipment and reagents, and services. The application segment is characterized by research and therapeutics and diagnostics. The report also includes an overview of the regulatory landscape for oligonucleotides.

The report also focuses on the regional segmentation of the market. The regions covered in this study include North America, Europe, the Asia-Pacific and the rest of the world (RoW), with a focus on major countries in these regions.

The report focuses on the major driving trends and challenges affecting the market and vendor landscape. It analyzes environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also includes a dedicated section of company profiles, detailing leading market companies.

Report Includes

• 64 data tables and 55 additional tables
• In-depth analysis of the global oligonucleotides market
• Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects for the global oligonucleotide synthesis market, accompanied by a market share analysis by product, application and region
• Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations, prospects and the impact of macroeconomic factors
• Insights derived from Porter's Five Forces model, as well as global supply chain analyses
• Patent review, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Company profiles of major players within the industry, including Alnylam Pharmaceuticals Inc., Biogen/Ionis Pharmaceuticals Inc., Novartis AG, and Sarepta Therapeutics Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Types of Oligonucleotides
• Mechanisms of Action of Oligonucleotides
• Oligonucleotide Synthesis Processes
• Solid Phase Chemical Synthesis
• Porter's Five Forces Analysis in the Global Oligonucleotides Market
• Macroeconomic Factor Analysis
• Impact of the U.S. Tariffs
• Growing Rare Disease Funding
• Geopolitical Factors

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Growing Focus on Personalized Medicine
• Increasing Use of Synthesized Oligos in Therapeutic Applications
• Rising Prevalence of Rare Diseases
• Market Restraints/Challenges
• Product Withdrawals and Clinical Trial Failures
• Complexities Associated with Oligos Manufacturing
• High Treatment Costs of Oligonucleotide Therapeutics
• Market Opportunities
• Expanding Application Areas of Oligonucleotides
• Expansion of Companies
• DNA Nanotechnology for Drug Delivery

Chapter 4 Regulatory Landscape

• Regulatory Paths for Oligonucleotide Therapeutics
• U.S.
• European Union
• Asia-Pacific

Chapter 5 Emerging Technologies

• Key Takeaways
• Emerging Technologies
• Enzymatic Oligonucleotide Synthesis
• Advances in RNAi Delivery Systems
• Circulating miRNA Diagnostics for Noninvasive Health Monitoring
• Innovative Oligonucleotide Conjugation Methods
• Pipeline Analysis

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis by Product Type
• Key Takeaways
• Oligonucleotide Drugs
• Synthesized Oligos
• Equipment and Reagents
• Services
• Market Analysis by Application
• Key Takeaways
• Diagnostics and Therapeutics
• Research
• Geographic Breakdown
• Market Analysis by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Industry Structure
• Company Share Analysis of the Global Oligonucleotides Market
• Strategic Analysis
• Funding Outlook

Chapter 8 Sustainability in the Global Oligonucleotides Market: An ESG Perspective

• Introduction to ESG
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• AGILENT TECHNOLOGIES INC.
• AJINOMOTO BIO-PHARMA
• ALNYLAM PHARMACEUTICALS INC.
• ASTELLAS PHARMA INC.
• BIOGEN
• CHARLES RIVER LABORATORIES
• EUROFINS GENOMICS
• GENSCRIPT
• INTEGRATED DNA TECHNOLOGIES INC.
• MERCK KGAA
• NOVARTIS AG
• NOVO NORDISK A/S
• REVVITY
• SAREPTA THERAPEUTICS INC.
• THERMO FISHER SCIENTIFIC INC.
• Emerging Startups/Market Disruptors